Literature DB >> 15308364

Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.

Arnaud Didierlaurent1, Juan-Carlos Ramirez, Magdalena Gherardi, Simone C Zimmerli, Marcus Graf, Hans-Acha Orbea, Giuseppe Pantaleo, Ralf Wagner, Mariano Esteban, Jean-Pierre Kraehenbuhl, Jean-Claude Sirard.   

Abstract

Efficient HIV vaccines have to trigger cell-mediated immunity directed against various viral antigens. However little is known about the breadth of the response induced by vaccines carrying multiple proteins. Here, we report on the immunogenicity of a construct harbouring a fusion of the HIV-1 IIIB gag, pol and nef genes (gpn) designed for optimal safety and equimolar expression of the HIV proteins. The attenuated poxviruses, MVA and NYVAC, harbouring the gpn construct, induced potent immune responses in conventional mice characterised by stimulation of Gpn-specific IFN-gamma-producing cells and cytotoxic T cells. In HLA-A2 transgenic mice, recombinant MVA elicited cytotoxic responses against epitopes recognised in most HLA-A2+ HIV-1-infected individuals. We also found that the MVA vaccine triggered the in vitro expansion of peripheral blood cells isolated from a HIV-1-seropositive patient and with similar specificity as found in immunised HLA-A2 transgenic mice. In conclusion, the synthetic HIV polyantigen Gpn delivered by MVA is immunogenic, efficiently processed and presented by human MHC class I molecules.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308364     DOI: 10.1016/j.vaccine.2004.02.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Authors:  José Luis Nájera; Carmen Elena Gómez; Elena Domingo-Gil; María Magdalena Gherardi; Mariano Esteban
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.

Authors:  Ningjie Hu; Richard Yu; Cecilia Shikuma; Bruce Shiramizu; Mario A Ostrwoski; Qigui Yu
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

4.  Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.

Authors:  Geert Leroux-Roels; Patricia Bourguignon; Julie Willekens; Michel Janssens; Frédéric Clement; Arnaud M Didierlaurent; Laurence Fissette; François Roman; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2014-01-03

5.  Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.

Authors:  Samantha Brandler; Alice Lepelley; Marion Desdouits; Florence Guivel-Benhassine; Pierre-Emmanuel Ceccaldi; Yves Lévy; Olivier Schwartz; Arnaud Moris
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

6.  Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Authors:  José Luis Nájera; Carmen Elena Gómez; Juan García-Arriaza; Carlos Oscar Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

7.  Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic.

Authors:  Max Corbett; Willy M Bogers; Jonathan L Heeney; Stefan Gerber; Christian Genin; Arnaud Didierlaurent; Herman Oostermeijer; Rob Dubbes; Gerco Braskamp; Stéphanie Lerondel; Carmen E Gomez; Mariano Esteban; Ralf Wagner; Ivanella Kondova; Petra Mooij; Sunita Balla-Jhagjhoorsingh; Niels Beenhakker; Gerrit Koopman; Sjoerd van der Burg; Jean-Pierre Kraehenbuhl; Alain Le Pape
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

8.  Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Authors:  Lucas Sánchez-Sampedro; Carmen Elena Gómez; Ernesto Mejías-Pérez; Eva Pérez-Jiménez; Juan Carlos Oliveros; Mariano Esteban
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

9.  Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.

Authors:  Petra Mooij; Sunita S Balla-Jhagjhoorsingh; Gerrit Koopman; Niels Beenhakker; Patricia van Haaften; Ilona Baak; Ivonne G Nieuwenhuis; Ivanela Kondova; Ralf Wagner; Hans Wolf; Carmen E Gómez; José L Nájera; Victoria Jiménez; Mariano Esteban; Jonathan L Heeney
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

10.  Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus.

Authors:  Amanda J Williams; Lyn M O'Brien; Robert J Phillpotts; Stuart D Perkins
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.